INVO Fertility (NASDAQ: IVF) lifts clinic revenue 28% as loss narrows

What happened

INVO Fertility, Inc. (NASDAQ: IVF) lifted clinic revenue 28% to $2.21 million from $1.72 million in the third quarter. That is $485,364 more than a year earlier.

Total revenue rose 26% to $2.22 million from $1.76 million. Net loss narrowed to $2.1 million from $3.4 million.

For holders, the clinics are still adding sales while losses shrink. The company is not yet profitable as a whole.

INVO Fertility has four operating fertility clinics in the United States. It plans to build, acquire and run fertility clinics and related businesses and technologies. It also still sells INVOcell to third-party clinics.

Key numbers

Metric Latest Change Source
Revenue $2.22 million from $1.76 million, +26% Consolidated statements of operations
Clinic revenue $2.21 million from $1.72 million, +28% Consolidated statements of operations
Net loss $2.1 million from $3.4 million, -$1.3 million Consolidated statements of operations
Clinic-Level Adjusted EBITDA $292,114 from $243,120, +20.1% Press release non-GAAP discussion
Cash $3.70 million from $2.08 million, +$1.62 million Consolidated balance sheets
Current liabilities $4.46 million from $10.33 million, -$5.87 million Consolidated balance sheets

Read more: INVO Fertility (IVF) company research

Why it matters

Loss from operations improved to $1.5 million from $1.6 million. Consolidated Adjusted EBITDA was a loss of $1.0 million, versus a loss of $0.9 million a year earlier.

Corporate overhead still kept consolidated Adjusted EBITDA negative.

Clinic-Level Adjusted EBITDA stayed positive for the seventh straight quarter at $292,114, up from $243,120.

That clinic profit has to cover corporate costs before the company can turn a consolidated profit. It does not yet.

The company said the planned Birmingham acquisition transition cut clinic-level contribution by about $193,000.

Management said new tools are being rolled out across its practices to cut time spent on documentation and administrative work. It expects them to improve patient experience and clinic-level efficiency.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

Where the growth came from

Management said revenue grew at the Wisconsin and Atlanta clinics. It said Wisconsin joined the Progyny network in the first quarter, which widened access for patients with Progyny coverage.

The Indiana clinic, acquired in February, and the Birmingham clinic, acquired in late June, each added a full quarter of revenue.

Product revenue fell to $15,069 from $34,871. Sales to Indiana and Birmingham were eliminated once those clinics became consolidated subsidiaries.

INVO Fertility said it attended the American Society for Reproductive Medicine Scientific Congress Expo in Baltimore in October 2026. It said the meeting led to more potential acquisition opportunities.

Balance sheet and liquidity

Cash was $3.70 million at Sept. 30. Current liabilities were $4.46 million, down from $10.33 million at Dec. 31, 2025.

The balance sheet is cleaner than at year-end, but cash still trails near-term obligations.

INVO Fertility said assets rose $5.3 million and liabilities fell $5.5 million. Net equity reached $18.0 million, or $15.09 per share.

The company had 1,192,860 shares of common stock outstanding as of Nov. 13, 2026.

What's next

INVO Fertility will host a webcast on Monday, Nov. 16, 2026, at 11:00 a.m. Eastern Time to discuss third-quarter results and give a business update.

Clinic growth that continues without leaning so heavily on acquisitions would strengthen the case. Another quarter of negative companywide Adjusted EBITDA would leave the turnaround unfinished.

More from OptimistFi

From OptimistFi Perps

Sources

Explore OptimistFi research on INVO Fertility, Inc.: https://optimistfi.com/stocks/IVF

Browse INVO Fertility, Inc. company coverage and explore the OptimistFi Thesis-Break Engine.

Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.

Find available research on the INVO Fertility, Inc. company page.

Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.